北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 妇科肿瘤中心  > 期刊论文
学科主题: 临床医学
题名:
Human Epididymis Protein 4 (HE4) as a Serum Tumor Biomarker in Patients With Ovarian Carcinoma
作者: Chang, Xiaohong1; Ye, Xue1; Dong, Li1; Cheng, Hongyan1; Cheng, Yexia1; Zhu, Lirong2; Liao, Qinping2; Zhao, Yang1; Tian, Li1; Fu, Tianyun1; Chen, Jun1; Cui, Heng1
关键词: Ovarian cancer ; Cancer biomarker ; HE4 ; CA 125 ; Improved diagnosis
刊名: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
发表日期: 2011-07-01
DOI: 10.1097/IGC.0b013e31821a3726
卷: 21, 期:5, 页:852-858
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Obstetrics & Gynecology
研究领域[WOS]: Oncology ; Obstetrics & Gynecology
关键词[WOS]: CANCER ; CA125 ; MASS
英文摘要:

Background: Ovarian cancer remains a leading cause of death from gynecological malignancy. Early diagnosis is the most important determinant of survival. For more than 25 years, cancer antigen 125 (CA 125) has been the criterion standard biomarker for the diagnosis and management of women with epithelial ovarian cancer. This study evaluated human epididymis protein 4 (HE4), a novel ovarian cancer biomarker, both alone and in combination with CA 125 as a diagnostic marker for ovarian cancer in a Chinese population.

Methods: Sera from 491 Chinese women with ovarian cancer or nonmalignant disorders and healthy women were analyzed. Sensitivities and specificities for both biomarkers and the combination were determined using predefined cutoffs (HE4 >150 pmol/L and CA 125 >35 U/mL) and receiver operator characteristic curves to define cutoffs based on 95% and 98% sensitivities.

Results: At baseline, serum HE4 and CA 125 levels were significantly higher in the ovarian cancer group versus the 5 reference groups. Using predefined cutoffs, HE4 specificity for ovarian cancer ranged from 90% to 100%; CA 125 specificity ranged from 36% (benign gynecologic disease) to 99%. Combining both markers yielded specificity for ovarian cancer of 100%. Using receiver operator characteristic curve analysis, the cutoff for 95% and 98% specificity was 102.6 and 150.2 pmol/L for HE4, respectively, and 127.2 and 325.5 U/mL for CA 125, respectively; the sensitivity of CA 125 for distinguishing ovarian cancer from benign gynecologic disease was 54% (95% specificity) and 28% (98% specificity), improving to 78% and 68%, respectively, with the addition of HE4.

Conclusions: Human epididymis protein 4 used in conjunction with CA 125 yields improved specificity for ovarian cancer compared with the use of CA 125 alone, generally similar to results seen in non-Chinese populations.

语种: 英语
所属项目编号: 7092108
项目资助者: The Beijing Municipal Natural Science Foundation ; Fujirebio Diagnostics, Inc
WOS记录号: WOS:000291972600012
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/58707
Appears in Collections:北京大学第二临床医学院_妇科肿瘤中心_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Peoples Hosp, Gynecol Oncol Ctr, Beijing 100044, Peoples R China
2.Peking Univ, Hosp 1, Dept Gynecol & Obstet, Beijing 100044, Peoples R China

Recommended Citation:
Chang, Xiaohong,Ye, Xue,Dong, Li,et al. Human Epididymis Protein 4 (HE4) as a Serum Tumor Biomarker in Patients With Ovarian Carcinoma[J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER,2011,21(5):852-858.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Chang, Xiaohong]'s Articles
[Ye, Xue]'s Articles
[Dong, Li]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Chang, Xiaohong]‘s Articles
[Ye, Xue]‘s Articles
[Dong, Li]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace